Research and Development

Novartis has received a major boost in its efforts to broaden use of its CDK4/6 inhibitor, by receiving a breakthrough …

Mallinckrodt has endured a tough 2017, with its share price falling by half over the course of the year. This …

There was ample warning that the NHS looked set to face another difficult winter season, the predictions now look to …

A group of researchers at Lancaster University have identified a drug currently used to treat type 2 diabetes that has …

After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …

Pharmafile.com looks ahead to signpost what we expect will be the key industry trends through the course of 2018.The value of …

Only a few months ago, it was announced that Eisai had decided to opt into the development process of BAN2401. …

New research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg-Kimmel Cancer Institute for Cancer Immunotherapy has indicated that …

Continuing on from this week’s earlier feature on the rare disease situation in the US, Pharmafile moves its attention onto …

AbbVie posted strong results from its Phase 3 trial into its treatment for rheumatoid arthritis, upadacitinib, but discussions of the …

Johnson & Johnson has been fined by France’s competition authority, Autorité de la Concurrence, after it alleges the company had …

Genentech has followed in the footsteps of its parent company by signing a drug discovery agreement with DiCE Molecules. The …

NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia (interferon beta 1b) for the treatment of …

British pharmaceutical giant GlaxoSmithKline has been ordered to pay back £1.5 million to the Scottish Government because of its failure …

The FDA handed approval to Spark Therapeutics’ gene therapy for an inherited eye disorder, making it the first treatment of …